Custom mRNA vaccine takes on rare endocrine cancers
NCT ID NCT06141369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in each person's tumor. The main goals are to see if the vaccine is safe and tolerable, and to check if it triggers an immune response against the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Massive database study probes link between popular diabetes drugs and rare thyroid cancer
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
- Promising drug trial for rare pancreatic cancer stopped early
- New imaging agent could improve detection of rare cancers